Key Takeaways
- ZIVO Bioscience signs two agreements with a global animal health company to evaluate immune-enhancing compounds
- Studies will focus on coccidiosis and viral diseases with significant impact on poultry health and mortality
- Research is fully funded by the partner and aims to complement existing poultry vaccination strategies
- Positive trial results may lead to regulatory submissions and future commercial agreements
- The collaboration may expand to include additional livestock and companion animal species
ZIVO Bioscience to Explore Poultry Health Applications Through Strategic Research Agreements
ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company developing products from proprietary algal cultures, has announced a collaboration with one of the world’s leading animal health companies. The relationship focuses on evaluating ZIVO’s immune-boosting compounds in poultry, with plans to broaden applications to other animal segments over time.
“This collaboration supports our strategy to partner with a major animal health company that brings scientific expertise and R&D infrastructure to advance our innovations to global markets efficiently and at scale,” said John Payne, Chairman and CEO of ZIVO Bioscience.
Initial Studies Target Coccidiosis and Viral Disease Models For ZIVO
Under the collaboration, two separate research agreements have been signed. The first study will examine the use of ZIVO’s proprietary actives in addressing coccidiosis, a parasitic disease that presents a major challenge to poultry producers worldwide. The 42-day trial will test the co-administration of ZIVO’s compound alongside the partner’s existing vaccine and evaluate additional performance parameters using tissue and plasma samples.
The second study will evaluate the compound’s impact on a viral disease with high mortality and no current cure. This study leverages a well-established in vivo model and seeks to determine the compound’s potential to reduce disease severity and spread. The virus was selected based on its relevance as a model for multiple viral diseases affecting poultry.
These trials follow prior ZIVO data suggesting reduced severity of low-pathogenic avian influenza (LPAI) in treated birds and are intended to support regulatory filings with the USDA’s Center for Veterinary Biologics and provide a foundation for commercial validation.
Study Goals and Potential Outcomes
Both research programs aim to test the ability of ZIVO’s compounds to:
- Reduce the time between immunization and protective immunity
- Protect birds during the pre-immunity window
- Strengthen immune responses post-vaccination
- Mitigate immunosuppression and susceptibility to secondary infections
The studies are fully funded by the collaborating company, and favorable results may lead to broader agreements targeting additional diseases and species.
“We are aligned with this company on the broad applicability of our immune-modulating technology and its potential to create a disruptive, non-antibiotic therapeutic platform,” Payne added. “Adding ZIVO’s therapeutic products to their portfolio would represent an entirely new market for our partner, and the significant prior work we’ve done provides high confidence for success.”
1 Comment